GlassScriptPhysician profile
Marco Luna
NPI 1639834252
$355.54
in general payments reported to CMS, 2019-2025
10 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.05 · 2022: $19.60 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $132.85 | 2021-2025 | Airsupra |
| Avita Medical Americas, LLC | $39.50 | 2025 | Recell, Permeaderm, Cohealyx |
| Kerecis Limited | $36.08 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Heron Therapeutics, INC. | $29.63 | 2025 | Aponvie |
| Smith+Nephew, INC. | $25.39 | 2025 | Stravix |
| La Jolla Pharmaceutical Company | $22.63 | 2025 | Giapreza |
| Glaxosmithkline, LLC. | $19.60 | 2022 | |
| Alkermes, INC. | $19.54 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.52 | 2021 | |
| Amarin Pharma, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.